Your browser doesn't support javascript.
loading
The Minimal Clinically Important Difference in Glaucoma Medication Adherence: Interviews of Glaucoma Experts.
Kolli, Ajay; Daniel-Wayman, Shelby; Newman-Casey, Paula Anne.
Afiliação
  • Kolli A; University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Daniel-Wayman S; Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, USA.
  • Newman-Casey PA; Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, USA, panewman@med.umich.edu.
Ophthalmic Res ; 64(3): 524-528, 2021.
Article em En | MEDLINE | ID: mdl-33171476
ABSTRACT
Poor adherence to glaucoma medications is associated with progressive vision loss. While many interventions have sought to increase glaucoma medication adherence, the amount by which adherence must increase to have a clinically significant effect remains unknown. To generate a hypothesized minimal clinically important difference (MCID) for glaucoma medication adherence, we conducted interviews with glaucoma experts. Semi-structured interviews were conducted with members of the American Glaucoma Society. MCID was defined in 2 ways (1) the incremental increase in the average percentage of eye drops a patient takes at roughly the correct time and (2) the incremental increase in the proportion of a patient population who attain good adherence. Good adherence was defined as taking more than 80% of drops at approximately the prescribed dose time. Expert opinions on the MCID for glaucoma medication adherence and open-ended responses were recorded through field notes. Twenty-five experts were interviewed. They estimated the MCID for average individual adherence levels as 17.7% (95% CI 14.6, 20.8). Experts estimated the MCID for the proportion of patients in a practice who attain good adherence (defined as >80% of eye drops taken as prescribed) as 18.5% (95% CI 15.6, 21.5). The most common identified themes were that the MCID should take into account the cost of the intervention and the burden to the ophthalmologist and to the practice, where experts thought that more costly interventions or those that required more physician time should have larger MCIDs. Based on expert opinion, we hypothesized that the MCID for glaucoma medication adherence is between 15 and 20%. However, the MCID for a given intervention must take into account several factors, including intervention cost and physician burden. This hypothesis may facilitate the design and implementation of future studies to objectively determine an MCID for glaucoma medication adherence.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glaucoma / Diferença Mínima Clinicamente Importante Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: Ophthalmic Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glaucoma / Diferença Mínima Clinicamente Importante Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: Ophthalmic Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos